Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.39 |
| ▸ | EED | O75530 | 1/20 | 0.39 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.39 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.39 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.39 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17304017 | 0.94 | PDE4B (0.44) | MAPTKDM4ETHRBDPP4TRPC6 | |
| SCHEMBL17304050 | 0.91 | MAPT (0.47) | MAPTKDM4ETHRBDPP4TRPC6 | |
| SCHEMBL17879568 | 0.89 | DPP4 (0.35) | MAPTKDM4ETHRBDPP4TRPC6 | |
| SCHEMBL17303726 | 0.89 | KDM4E (0.38) | MAPTKDM4ETHRBDPP4PDE4B | |
| SCHEMBL17304222 | 0.89 | SCN9A (0.42) | MAPTKDM4ETHRBDPP4ALDH1A1 | |
| SCHEMBL19896475 | 0.88 | TRPC6 (0.45) | TRPC6ALKPDE4B | |
| SCHEMBL17303745 | 0.88 | KDM4E (0.48) | MAPTKDM4ETHRBHTTALDH1A1 | |
| SCHEMBL17304040 | 0.88 | MAPT (0.43) | MAPTKDM4ETHRBDPP4HTT | |
| SCHEMBL28007082 | 0.86 | DPP4 (0.45) | MAPTKDM4ETHRBDPP4TRPC6 | |
| SCHEMBL17303744 | 0.86 | PDE4B (0.48) | MAPTKDM4ETHRBDPP4GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119899173-A | Preparation method of ceritinib as toxic impurity nitrosoceritinib of ceritinib gene | 南京亿华药业有限公司 | 2025-04-29 | — | — | CN | claimed |
| CN-115215788-B | Preparation method of ceritinib key intermediate | 苏州凯瑞医药科技有限公司 | 2023-09-22 | — | — | CN | claimed |
| CN-115215788-A | Preparation method of ceritinib key intermediate | 苏州凯瑞医药科技有限公司 | 2022-10-21 | — | — | CN | claimed |
| CN-119899173-A | Preparation method of ceritinib as toxic impurity nitrosoceritinib of ceritinib gene | 南京亿华药业有限公司 | 2025-04-29 | — | — | CN | disclosed |
| US-20240336643-A1 | BIFUNCTIONAL COMPOUNDS THAT DEGRADE ALK AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-10-10 | — | — | US | disclosed |
| EP-4362939-A1 | BIFUNCTIONAL COMPOUNDS THAT DEGRADE ALK AND USES THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| CN-115215788-B | Preparation method of ceritinib key intermediate | 苏州凯瑞医药科技有限公司 | 2023-09-22 | — | — | CN | disclosed |
| CN-115215788-B | Preparation method of ceritinib key intermediate | 苏州凯瑞医药科技有限公司 | 2023-09-22 | — | — | CN | disclosed |
| US-20230158152-A1 | PROTEOLYSIS REGULATOR AND METHOD FOR USING SAME | MEDSHINE DISCOVERY INC. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230158152-A1 | PROTEOLYSIS REGULATOR AND METHOD FOR USING SAME | MEDSHINE DISCOVERY INC. (CN) | 2023-05-25 | — | — | US | disclosed |
| WO-2023278325-A1 | BIFUNCTIONAL COMPOUNDS THAT DEGRADE ALK AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| EP-2311807-A1 | Compounds and composition as protein kinase inhibitors | IRM LLC (BM) | 2011-04-20 | — | — | EP | disclosed |
| EP-2311807-A1 | Compounds and composition as protein kinase inhibitors | IRM LLC (BM) | 2011-04-20 | — | — | EP | disclosed |
| EP-2271630-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009126515-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-10-15 | — | — | WO | disclosed |
| EP-2091918-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-08-26 | — | — | EP | disclosed |
| US-20080176881-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-07-24 | — | — | US | disclosed |
| US-20080176881-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-07-24 | — | — | US | disclosed |
| US-20080176881-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-07-24 | — | — | US | disclosed |
| WO-2008073687-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176881-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ZAP70, IGF1R, PTK2 | MAPT 3102/4885KDM4E 1924/4885THRB 599/4885 |
| US-20230158152-A1 | PROTEOLYSIS REGULATOR AND METHOD FOR USING SAME | PSMA6, PSMC1, PSMA1 | MAPT 1812/4885KDM4E 1251/4885THRB 2698/4885 |
| US-20240336643-A1 | BIFUNCTIONAL COMPOUNDS THAT DEGRADE ALK AND USES THEREOF | ALK, JMJD7, ALKBH3 | MAPT 3459/4885KDM4E 1185/4885THRB 2334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.